Ten63 Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ten63 Therapeutics - overview
Established
2018
Location
Durham, NC, US
Primary Industry
Biotechnology
About
Based in Durham Fwy, North Carolina, US, and founded in 2018, Ten63 Therapeutics provides a platform, Copper, that leverages its proprietary physical models to allow its users to discover new therapeutics to targets previously believed undruggable. In February 2026, Ten63 Therapeutics raised USD 22 million in venture funding from Black Opal Ventures, Cape Fear BioCapital, Chugai Venture Fund, Duke Capital Partners, Gates Foundation Trust, K5 Global, Panorama, RYSE Asset Management, SF Holdings, Alexandria Venture Investments, Draper, Hatteras Venture Partners, Morpheus Ventures, and Yosemite Management. Ten63 Therapeutics is the developer of a platform that allows anyone to challenge diseases to a chess match, one that is played through evolutionary time. The result is novel therapeutics that are resilient to the emergence of drug resistance and able to modulate previously undruggable targets.
The company plans to utilize the February 2026 funding for development of a computational drug discovery platform and a small‑molecule program.
Current Investors
SOSV, IndieBio, Alexandria Venture Investments
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.ten63tx.com/
Verticals
Artificial Intelligence
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.